Fiche publication
Date publication
septembre 2026
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Dr RENOSI Florian
Tous les auteurs :
Orvain C, Higué J, Peterlin P, Dumas PY, Debrosses Y, Hospital MA, Tavernier E, Carre M, Barriere S, Couturier A, Cluzeau T, Chantzi AE, Aspas Requena G, Largeaud L, Bouvier A, Bidet A, Renosi F, Alary AS, Flandrin-Gresta P, Tondeur S, Veronese L, Pastoret C, Dadone-Montaudié B, Lachot S, Bertoli S, Chevallier P, Hunault M, Pigneux A, Récher C
Lien Pubmed
Résumé
Given the uncertainty regarding the optimal management of molecular relapse in patients with CBF or NPM1-mutated AML, we retrospectively analyzed the outcome of 121 adults from 12 centers with CBF (n=28) or NPM1-mutated (n=93) AML and first molecular relapse according to the salvage strategy used (upfront allogeneic HCT [n=19], intensive chemotherapy [IC; n=21], venetoclax and azacitidine [VEN-AZA]; n=70), and other strategies (n=11; including AZA, gemtuzumab ozogamicin, selective inhibitors). At three years, OS was not statistically different between the four groups (84% for upfront allo vs. 81% for IC vs. 79% for VEN-AZA vs. 64% for other, P=0.31). Allogeneic HCT was received by 98 patients (81%) with a cumulative incidence of allogeneic HCT at 12 weeks of 100% for upfront allo, 71% for IC, 73% for VEN-AZA, and 82% for other (P<0.001) with better outcomes in transplanted patients. In patients who received allogeneic HCT, type of salvage therapy was not statistically associated with post-HCT relapse, relapse-free survival, or OS. Our data suggests that upfront allogeneic is a valuable option, if feasible, while other salvage strategies are associated with favorable outcomes and relatively low non-relapse mortality after allogeneic HCT.
Référence
Blood Adv. 2026 09 1;:
